Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Richardet, Katriina Peltola, Ajjai S. Alva, Michael Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas C. Gauler, Christian K. Kollmannsberger, Fabio A. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir

Open source

DOI: 10.1002/cncr.33033
Published: 2020-07-16
Container: Cancer
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.33033,
  title = {Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial},
  author = {Robert J. Motzer and Bernard Escudier and Saby George and Hans J. Hammers and Sandhya Srinivas and Scott S. Tykodi and Jeffrey A. Sosman and Elizabeth R. Plimack and Giuseppe Procopio and David F. McDermott and Daniel Castellano and Toni K. Choueiri and Frede Donskov and Howard Gurney and Stéphane Oudard and Martin Richardet and Katriina Peltola and Ajjai S. Alva and Michael Carducci and John Wagstaff and Christine Chevreau and Satoshi Fukasawa and Yoshihiko Tomita and Thomas C. Gauler and Christian K. Kollmannsberger and Fabio A. Schutz and James Larkin and David Cella and M. Brent McHenry and Shruti Shally Saggi and Nizar M. Tannir},
  year = {2020},
  journal = {Cancer},
  doi = {10.1002/cncr.33033},
  url = {https://doi.org/10.1002/cncr.33033}
}

RIS

TY  - JOUR
TI  - Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
AU  - Robert J. Motzer
AU  - Bernard Escudier
AU  - Saby George
AU  - Hans J. Hammers
AU  - Sandhya Srinivas
AU  - Scott S. Tykodi
AU  - Jeffrey A. Sosman
AU  - Elizabeth R. Plimack
AU  - Giuseppe Procopio
AU  - David F. McDermott
AU  - Daniel Castellano
AU  - Toni K. Choueiri
AU  - Frede Donskov
AU  - Howard Gurney
AU  - Stéphane Oudard
AU  - Martin Richardet
AU  - Katriina Peltola
AU  - Ajjai S. Alva
AU  - Michael Carducci
AU  - John Wagstaff
AU  - Christine Chevreau
AU  - Satoshi Fukasawa
AU  - Yoshihiko Tomita
AU  - Thomas C. Gauler
AU  - Christian K. Kollmannsberger
AU  - Fabio A. Schutz
AU  - James Larkin
AU  - David Cella
AU  - M. Brent McHenry
AU  - Shruti Shally Saggi
AU  - Nizar M. Tannir
PY  - 2020
JO  - Cancer
DO  - 10.1002/cncr.33033
UR  - https://doi.org/10.1002/cncr.33033
ER  -

APA

Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Procopio, G., McDermott, D. F., Castellano, D., Choueiri, T. K., Donskov, F., Gurney, H., Oudard, S., Richardet, M., Peltola, K., Alva, A. S., Carducci, M., Wagstaff, J., Chevreau, C., Fukasawa, S., Tomita, Y., Gauler, T. C., Kollmannsberger, C. K., Schutz, F. A., Larkin, J., Cella, D., McHenry, M. B., Saggi, S. S., & Tannir, N. M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial. Cancer. https://doi.org/10.1002/cncr.33033

Source records

crossref · retrieved 2026-09-26T16:10:07.833Z